General Information
ISIS DM2 449884-CS4
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 (an Antisense Glucagon Receptor Antagonist) Administered Once Weekly for 26 Weeks in Patients with Type 2 Diabetes Being Treated with Metformin
| Protocol | 449884-CS4 |
|---|---|
| Identifier | 449884-CS4 Site No: 1850 |
| UID | 2d507358-deb6-4fb3-a550-50fb6ba4d3af |
| Status | Done - Archived |
| Phase | 2 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2015 |
| NCT Number | - |
| Created | 2015-06-02 16:01 |
| Last Updated | 2015-06-02 16:01 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2015-08-19 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | 2015-09-21 | No |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Sandoval, Larry | LSandoval | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | ISIS Pharmaceuticals |
|---|---|
| Division | Isis Pharmaceuticals |
| Team | Isis Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Medpace, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
